BEIJING (Reuters) – China has approved early human tests for two experimental vaccines to fight the new coronavirus that has killed more than 100,000 people worldwide, Xinhua state media reported on Tuesday.
The vaccines are being developed by a Beijing-based unit of Sinovac Biotech listed on Nasdaq, and by the Wuhan Institute of Biological Products, a subsidiary of the national group China National Pharmaceutical Group.
In March, China gets the go-ahead for another clinical trial for a coronavirus vaccine candidate developed by the Chinese Academy of Military Medical Sciences and the listed biotechnology company HK CanSino Bio, shortly after the drug developer American Moderna said it had started human testing for their vaccine with the National Institutes of Health in the United States.
Report by Roxanne Liu and Se Young Lee; Editing by Kim Coghill
Our standards:Principles of the Thomson Reuters Trust.